Brief: MiNK Therapeutics And First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial Of Agent-797 In Acute Lung Injury And Critical Illness
14/05/2026 12:33
May 14 (Reuters) - Mink Therapeutics Inc INKT.O: MINK THERAPEUTICS AND FIRST LVIV TERRITORIAL MEDICAL UNION INITIATE RANDOMIZED PHASE 2 TRIAL OF AGENT-797 IN ACUTE LUNG INJURY AND CRITICAL ILLNESS MINK THERAPEUTICS INC: PRELIMINARY DATA EXPECTED IN SECOND HALF OF 2026 Source text: ID:nGNX1W9HpP Further company coverage: INKT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mink Therapeutics
See all newsMiNK Therapeutics Q2 loss narrows on expense discipline
Brief: MiNK Therapeutics Q2 EPS USD -0.62
Mink Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: MiNK Therapeutics Says No Major Serious Adverse Events Attributed To Agent-797 In First Patients
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's